Response to comment on "Dosing implications for liposomal amphotericin B in pregnancy"

Pharmacotherapy. 2023 Sep;43(9):992. doi: 10.1002/phar.2864.

Authors

Niamh O'Grady¹, Matthew Davis¹, Dayna McManus¹, Jeffrey Topal², Marwan M Azar³, Neima Briggs²

Affiliations

¹ Department of Pharmacy, Yale-New Haven Hospital, New Haven, Connecticut, USA.
² Infectious Disease Section, Department of Internal Medicine, Yale-New Haven Hospital, New Haven, Connecticut, USA.
³ Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

PMID: 37701938
DOI: 10.1002/phar.2864

No abstract available

Publication types

Letter
Comment

MeSH terms

Amphotericin B* / administration & dosage
Female
Humans
Pregnancy

Substances

liposomal amphotericin B
Amphotericin B